+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

NBDF-Sanofi Career Development Award

National Bleeding Disorders Foundation

The NBDF-Sanofi Career Development Award (CDA) is generously sponsored by Sanofi. NBDF seeks research grant applications from established investigators, preferably at the assistant professor level or above, who have demonstrated a commitment to bleeding disorders research. We especially encourage innovative projects that promote the development of novel technologies and/or therapies to advance the field of bleeding disorders research.

Funding

NBDF will award up to $70,000 annually for a maximum of three years.

Scope of Research

NBDF is interested in funding innovative research studies in bleeding disorders to be carried out at the sub cellular, cellular, animal or human/patient levels.

While gene therapy has been an approach which has shown much promise in hemophilia, no one method has been demonstrated to be superior. Multiple experimental strategies may be undertaken to help find a “cure” for bleeding disorders. NBDF is seeking research proposals on the nature, propagation, and use of hematopoietic, liver, or stem cells as an approach for gene transfer in hemophilia or for other novel approaches for treating bleeding disorders.

Studies to evaluate the genetic and immunologic bases for inhibitor development may lead to strategies to circumvent this potential complication of clotting factor replacement and/or gene transfer. This research could provide the opportunity to determine the prognostic indicators that place patients at risk of inhibitor development. Inhibitor research may also lead to the development of synthetic replacement factor and gene therapy products with decreased immunogenicity. This includes research on genotype/phenotype relationships and susceptibility to inhibitors.

Structural studies of clotting factor proteins are needed in order to design more efficacious, longer-lived clotting factor proteins. Development of both small, biologically active, orally delivered molecules and improved protein delivery systems represent strategies that could lead to advances in our understanding of bleeding disorders. Better functional assays for clotting factor proteins are also needed. Reproducible, low-volume measure of factor VIII and factor IX activity in different animal models would greatly facilitate validation of in vivo gene therapy studies as well as innovative alternative treatment strategies.

Please see the NRB community-defined priorities below for a more comprehensive list of NBDF's Research Priorities.

All CDA research proposals are subjected to a rigorous peer review process. Applications will be reviewed on scientific merit and scored in terms of project significance, scientific approach, innovation, investigator qualifications and institutional environment.

Deadlines

All interested candidates need to request a ‘Letter of Intent’ (LOI) by the deadline. Late LOIs will not be accepted.

LOIs need to be submitted on institutional letterhead and will not be considered for review unless signed by the candidate. LOIs should be addressed to “Members of NBDF’s Research Review Committee,” be 1 to 1.5 pages in length, include a brief introduction of the candidate/researcher and ability to meet eligibility criteria, information about his/her mentor, and a brief description of the proposed research project. Letters must be accompanied by a CV (NIH-style biosketch preferred) for both the candidate and his/her mentor and submitted as a single PDF.

LOIs will be evaluated by members of NBDF’s Research Review Committee based on the candidate’s eligibility and relevance of the proposed research to the field of bleeding disorders. The committee will then collectively decide which candidates will be invited to submit a full application. The selected candidates will have until noted deadlines above to submit their full CDA application to NBDF. Applications that do not arrive by the deadline will not be accepted.

CDA applications are subjected to a rigorous peer review process. Proposals are to be reviewed on scientific merit and scored in the areas of project significance, scientific approach, innovation, investigator qualifications and research environment.

AI Based Application Success Predictor

Based on available information:

✅ NBDF does not publicly list or administer competitive research grants with structured success predictors or scoring criteria.

❌ Therefore, there are no “grant success predictors” specific to NBDF research funding to monitor or notify you about at this time.

The foundation’s activities center on empowerment, support, education, and advocacy rather than funded research programs, which is why explicit grant success predictors analogous to research grant criteria are not found in its public resources.

📌 Summary

The National Bleeding Disorders Foundation (NBDF) is a nonprofit dedicated to community support, education, advocacy, and resources for people with bleeding disorders.

It does not currently offer traditional competitive research grants with public evaluation criteria.

As a result, no grant success predictors specific to NBDF funding opportunities are published and no notifications can be generated for them.

Specialties

Hematology

Orthopedics

Eligibility Requirements

Career Development Award (CDA) candidates must hold a MD, PhD, or equivalent degree, with no more than six years of postdoctoral years of experience in hematology, nor more than six years since completion of medical training. United States citizenship is not required, but applicants must be affiliated with or be faculty members of a U.S.-based organization such as universities, colleges, hospitals or laboratories. Only non-commercial institutions and investigators associated with a non-commercial institution are eligible to apply for this award.

The CDA award recipient will be expected to spend at least 75% of their working time on the funded research project. The CDA recipient and his/her mentor are also expected to remain at their institution for the duration of the project. For the application, letters of support from appropriate institutional officials (department chair and financial grants officer) indicating the institution’s commitment to allow the candidate to focus his/her efforts on the stated research project will be required.

Sponsor Details

Sponsor Institute/Organizations: National Bleeding Disorders Foundation

Sponsor Type: Corporate/Non-Profit

Address: 1230 Avenue of the Americas 16th Floor, New York, NY 10020

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity